BFC Planning’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
BFC Planning's PTGX Position: Q3 2026 in Review
BFC Planning opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 11 shares worth $1.55K. The stake represents ﹤0.01% of the portfolio and ranks #3064 among its holdings. This is a return to the name: BFC Planning previously reported a position in PTGX as recently as Q4 2025.
BFC Planning first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.37K in Q4 2025. 294 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- BFC Planning held 11 shares of Protagonist Therapeutics worth $1.55K as of Q3 2026.
- Protagonist Therapeutics was a new BFC Planning position in Q3 2026.
- Protagonist Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3064 holding.
- BFC Planning first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
- BFC Planning's Protagonist Therapeutics position peaked at $4.37K in Q4 2025.
- 294 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.